亚辉龙：取得人绒毛膜促性腺激素及β亚单位测定试剂盒医疗器械注册证

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for a new product, enhancing its product line in the field of reproductive hormones and tumor markers [1] Product Development - The newly approved product is a human chorionic gonadotropin and β-subunit assay kit (chemiluminescence method) for the quantitative determination of human chorionic gonadotropin and β-subunit levels in human serum and/or plasma [1] - This product enriches the company's fully automated chemiluminescence product line [1] Market Impact - The sales performance of the new product will be influenced by market conditions, making it difficult for the company to predict its impact on future performance [1]